Physician profile
Sonali Narain
NPI 1124250287
$53,756.81
in general payments reported to CMS, 2019-2025
16 companies · $8,569 in 2025
The $8,569 reported for 2025 was more than what 89% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,029 · 2020: $124 · 2021: $2,595 · 2022: $12K · 2023: $20K · 2024: $8,736 · 2025: $8,569.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $16K · Honoraria: $7,596 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $5,778 · Consulting Fee: $4,926 · Food and Beverage: $2,652.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $16,318.98 |
| Honoraria | $7,596.49 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $5,778.24 |
| Consulting Fee | $4,925.58 |
| Food and Beverage | $2,651.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $16,800.46 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $14,098.24 | 2022-2025 | |
| Janssen Scientific Affairs, LLC | $12,355.28 | 2022-2025 | Tremfya |
| Abbvie INC. | $4,278.19 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $2,957.34 | 2023 | |
| Csl Behring | $2,028.60 | 2019 | |
| Genentech, INC. | $577.44 | 2025 | |
| Assertio Therapeutics, INC. | $254.12 | 2022 | |
| Alexion Pharmaceuticals, INC. | $150.00 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $133.05 | 2024 | |
| Amgen INC. | $124.09 | 2020 |
5 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sonali Narain listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.